New Parkinson's collaboration targets LRRK2 kinase inhibitors
This article was originally published in Scrip
Executive Summary
Ipsen and Oncodesign, both of France, have entered into a research collaboration to discover and develop novel LRRK2 kinase inhibitors as therapeutic agents against Parkinson's disease and for potential additional uses in other therapeutic areas.